Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1908 9
1909 16
1910 25
1911 15
1912 23
1913 50
1914 36
1915 10
1916 9
1917 5
1918 16
1919 3
1920 10
1921 3
1922 14
1923 18
1924 5
1925 6
1926 3
1927 1
1928 7
1929 2
1931 4
1932 2
1933 3
1934 1
1938 2
1939 2
1940 2
1941 2
1945 1
1946 4
1947 3
1948 2
1949 2
1950 4
1951 2
1953 2
1954 2
1955 2
1956 1
1957 1
1958 2
1959 3
1960 2
1961 2
1962 3
1963 3
1964 2
1966 2
1967 7
1968 4
1969 2
1970 4
1971 2
1972 5
1973 3
1974 9
1975 8
1976 16
1977 14
1978 12
1979 11
1980 12
1981 12
1982 17
1983 24
1984 20
1985 27
1986 25
1987 27
1988 28
1989 31
1990 39
1991 46
1992 43
1993 41
1994 54
1995 45
1996 49
1997 62
1998 46
1999 52
2000 74
2001 78
2002 62
2003 63
2004 67
2005 99
2006 97
2007 90
2008 91
2009 95
2010 102
2011 105
2012 114
2013 144
2014 185
2015 208
2016 223
2017 202
2018 188
2019 212
2020 241
2021 286
2022 276
2023 325
2024 121

Text availability

Article attribute

Article type

Publication date

Search Results

4,466 results

Results by year

Filters applied: . Clear all
Page 1
Changes in USDA food composition data for 43 garden crops, 1950 to 1999.
Davis DR, Epp MD, Riordan HD. Davis DR, et al. J Am Coll Nutr. 2004 Dec;23(6):669-82. doi: 10.1080/07315724.2004.10719409. J Am Coll Nutr. 2004. PMID: 15637215
After adjusting for differences in moisture content, we calculate ratios of nutrient contents, R (1999/1950), for each food and nutrient. To evaluate the foods as a group, we calculate median and geometric mean R-values for the 13 nutrients and water. ...Depending o …
After adjusting for differences in moisture content, we calculate ratios of nutrient contents, R (1999/1950), for each food and nutri …
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c).
Fiskus W, Boettcher S, Daver N, Mill CP, Sasaki K, Birdwell CE, Davis JA, Takahashi K, Kadia TM, DiNardo CD, Jin Q, Qi Y, Su X, McGeehan GM, Khoury JD, Ebert BL, Bhalla KN. Fiskus W, et al. Among authors: davis ja. Blood Cancer J. 2022 Jan 11;12(1):5. doi: 10.1038/s41408-021-00603-3. Blood Cancer J. 2022. PMID: 35017466 Free PMC article.
Synergy with the MI-based combinations is preserved against MLL1-r AML cells expressing FLT3 mutation, also CRISPR-edited to introduce mtTP53. These findings highlight the promise of clinically testing these MI-based combinations against AML harboring MLL1-r or mtNP …
Synergy with the MI-based combinations is preserved against MLL1-r AML cells expressing FLT3 mutation, also CRISPR-edited to introduc …
Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis.
Siafis S, Wu H, Wang D, Burschinski A, Nomura N, Takeuchi H, Schneider-Thoma J, Davis JM, Leucht S. Siafis S, et al. Among authors: davis jm. Mol Psychiatry. 2023 Aug;28(8):3267-3277. doi: 10.1038/s41380-023-02203-y. Epub 2023 Aug 3. Mol Psychiatry. 2023. PMID: 37537284 Free PMC article.
We also examined the relationship between dopamine D(2) receptor (D(2)R) occupancy and ORs by estimating occupancies from administrated doses. ...There was very low quality of findings for cariprazine, iloperidone, and zotepine, and no data for clozapine. The D(2)R …
We also examined the relationship between dopamine D(2) receptor (D(2)R) occupancy and ORs by estimating occupancies from administrat …
Human genome meeting 2016 : Houston, TX, USA. 28 February - 2 March 2016.
Srivastava AK, Wang Y, Huang R, Skinner C, Thompson T, Pollard L, Wood T, Luo F, Stevenson R, Polimanti R, Gelernter J, Lin X, Lim IY, Wu Y, Teh AL, Chen L, Aris IM, Soh SE, Tint MT, MacIsaac JL, Yap F, Kwek K, Saw SM, Kobor MS, Meaney MJ, Godfrey KM, Chong YS, Holbrook JD, Lee YS, Gluckman PD, Karnani N; GUSTO study group; Kapoor A, Lee D, Chakravarti A, Maercker C, Graf F, Boutros M, Stamoulis G, Santoni F, Makrythanasis P, Letourneau A, Guipponi M, Panousis N, Garieri M, Ribaux P, Falconnet E, Borel C, Antonarakis SE, Kumar S, Curran J, Blangero J, Chatterjee S, Kapoor A, Akiyama J, Auer D, Berrios C, Pennacchio L, Chakravarti A, Donti TR, Cappuccio G, Miller M, Atwal P, Kennedy A, Cardon A, Bacino C, Emrick L, Hertecant J, Baumer F, Porter B, Bainbridge M, Bonnen P, Graham B, Sutton R, Sun Q, Elsea S, Hu Z, Wang P, Zhu Y, Zhao J, Xiong M, Bennett DA, Hidalgo-Miranda A, Romero-Cordoba S, Rodriguez-Cuevas S, Rebollar-Vega R, Tagliabue E, Iorio M, D’Ippolito E, Baroni S, Kaczkowski B, Tanaka Y, Kawaji H, Sandelin A, Andersson R, Itoh M, Lassmann T; The FANTOM5 Consortium; Hayashizaki Y, Carninci P, Forrest ARR, Semple CA, Rosenthal EA, Shirts B, Amendola L, Gallego C, Horike-Pyne… See abstract for full author list ➔ Srivastava AK, et al. Among authors: davis t. Hum Genomics. 2016 May 26;10 Suppl 1(Suppl 1):12. doi: 10.1186/s40246-016-0063-5. Hum Genomics. 2016. PMID: 27294413 Free PMC article.
Karaca, Y. Bayram, M. K. Eldomery, J. Posey, H. Doddapaneni, J. Hu, V. R. Sutton, D. M. Muzny, E. A. Boerwinkle, D. Valle, J. R. Lupski, R. ...Boerwinkle, R. Weinshilboum, R. Gibbs O38 Melanoma reprogramming state correlates with response to CTL …
Karaca, Y. Bayram, M. K. Eldomery, J. Posey, H. Doddapaneni, J. Hu, V. R. Sutton, D. M. Muzny, E. A. Boerwinkle, D. Valle, J. R …
Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
Granger K, Gaffney KJ, Davis JA. Granger K, et al. Among authors: davis ja. J Oncol Pharm Pract. 2023 Apr;29(3):722-726. doi: 10.1177/10781552231154809. Epub 2023 Feb 12. J Oncol Pharm Pract. 2023. PMID: 36775940 Review.
CONCLUSION: Teclistamab is the newest agent granted FDA approval for use in R/R multiple myeloma and represents a promising new option for patients. Ongoing trials are investigating teclistamab and other novel bispecific antibodies in the upfront and R/R …
CONCLUSION: Teclistamab is the newest agent granted FDA approval for use in R/R multiple myeloma and represents a promising ne …
Neuropathologic validation of the Alzheimer's Questionnaire.
Mohebpour I, Malek-Ahmadi M, Virden T 3rd, Breitmeyer A, Sabbagh MN, Auman B, Belden CM, Choudhury P, Arch A, Davis K, Cline C, Moorley N, Atri A, Serrano G, Beach TG. Mohebpour I, et al. Among authors: davis k. Aging Clin Exp Res. 2022 Nov;34(11):2905-2909. doi: 10.1007/s40520-022-02222-9. Epub 2022 Aug 29. Aging Clin Exp Res. 2022. PMID: 36031683 Free PMC article.

Semi-quantitative measures of NP and NFT pathology were correlated with the AQ, Clinical Dementia Rating Sum of Boxes (CDR-SOB), and the Mini-Mental State Exam (MMSE). The AQ correlated significantly (p < 0.001) with NP load (r = 0.37) and NFT load (r = 0.57). Th

…
Semi-quantitative measures of NP and NFT pathology were correlated with the AQ, Clinical Dementia Rating Sum of Boxes (CDR-SOB), and the Min …
Polatuzumab Vedotin for the Front-Line Treatment of Diffuse Large B-Cell Lymphoma: A New Standard of Care?
Davis JA, Shockley A, Herbst A, Hendrickson L. Davis JA, et al. J Adv Pract Oncol. 2023 Jan;14(1):67-72. doi: 10.6004/jadpro.2023.14.1.6. Epub 2023 Feb 1. J Adv Pract Oncol. 2023. PMID: 36741209 Free PMC article.
For nearly 2 decades, standard front-line treatment has consisted of chemoimmunotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Numerous trials have unsuccessfully attempted to achieve better outcomes in these patients. ...This …
For nearly 2 decades, standard front-line treatment has consisted of chemoimmunotherapy with rituximab, cyclophosphamide, doxorubicin, vincr …
The renin-angiotensin system in central nervous system tumors and degenerative diseases.
Haron S, Kilmister EJ, Davis PF, Stylli SS, Mantamadiotis T, Kaye AH, Hall SR, Tan ST, Wickremesekera AC. Haron S, et al. Among authors: davis pf. Front Biosci (Landmark Ed). 2021 Sep 30;26(9):628-642. doi: 10.52586/4972. Front Biosci (Landmark Ed). 2021. PMID: 34590472 Free article. Review.
The main effector of the RAS is ATII which exerts its effect by binding to AT(1)R and AT(2)R through two competitive arms: an ACE1/ATII/AT(1)R axis, which is involved in regulating oxidative stress and neuroinflammation pathways, and an ATII/AT(2)R and …
The main effector of the RAS is ATII which exerts its effect by binding to AT(1)R and AT(2)R through two competitive arms: an …
Empirically supported religious and spiritual therapies.
Hook JN, Worthington EL Jr, Davis DE, Jennings DJ 2nd, Gartner AL, Hook JP. Hook JN, et al. Among authors: davis de. J Clin Psychol. 2010 Jan;66(1):46-72. doi: 10.1002/jclp.20626. J Clin Psychol. 2010. PMID: 19904806 Review.
This article evaluated the efficacy status of religious and spiritual (R/S) therapies for mental health problems, including treatments for depression, anxiety, unforgiveness, eating disorders, schizophrenia, alcoholism, anger, and marital issues. ...There was limited evide …
This article evaluated the efficacy status of religious and spiritual (R/S) therapies for mental health problems, including treatment …
Concentrated insulins: the new basal insulins.
Lamos EM, Younk LM, Davis SN. Lamos EM, et al. Among authors: davis sn. Ther Clin Risk Manag. 2016 Mar 9;12:389-400. doi: 10.2147/TCRM.S99855. eCollection 2016. Ther Clin Risk Manag. 2016. PMID: 27022271 Free PMC article. Review.
AREAS COVERED: This review highlights the published reports of the pharmacokinetic (PK) and glucodynamic properties of concentrated insulins: Humulin-R U500, insulin degludec U200, and insulin glargine U300, describes the clinical efficacy, risk of hypoglycemic, and metabo …
AREAS COVERED: This review highlights the published reports of the pharmacokinetic (PK) and glucodynamic properties of concentrated insulins …
4,466 results